Tumor Specific Response Articles & Analysis
12 news found
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. Vaccine Development Based on VLPs with MHC Complex To demonstrate and deliver specific tumor-associated MHC complex ...
The primary endpoint of the study is incidence and severity of treatment related adverse events and secondary endpoints include objective response rate, duration of response, progression-free survival and overall survival. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow ...
HB-200 was generally well tolerated, rapidly induced a high magnitude of tumor-specific T cells and showed early anti-tumor activity in these difficult-to-treat patients. ...
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 ...
Arenaviral immunotherapy activates against self-antigens Additional preclinical data (abstract #3298 and abstract #4198) showed antitumor activity with a single administration of replicating arenaviral immunotherapy targeting tumor self-antigens. Specifically, the arenaviral immunotherapy was able to overcome immune tolerance, induce potent T cell ...
Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy: Relevant neoantigens could be identified in all evaluable patients and TG4050 induced tumor specific T cell responses against multiple of these patient-specific neoantigen ...
Under the terms of the agreement, Zephyr will employ its proprietary AI and machine learning technology to identify targets suitable for activating T-cell-mediated anti-tumor responses. Specifically, Zephyr will evaluate a range of molecular and genetic data through in silico target discovery to uncover known, high potential ...
“PolyPEPI1018 previously demonstrated robust immune responses and initial efficacy in maintenance-stage therapy for mCRC in our completed Phase 1/2 trial. ...
The results from the explant model system show that treatment with ParvOryx leads to the induction of specific cytokines and chemokines as well as to a strong infiltration of CD8 T cells, the major effectors in the anti-tumor response. ...
The combination treatment was well tolerated by all patients and led to objective tumor response and significantly prolonged survival times. On the basis of compelling safety, tolerability and efficacy data stemming from both the rGBM trial and from the follow-up program, ORYX requested meetings with the regulatory authorities both in the EU and US to discuss ...
These patients showed favorable immunological signatures, like changes in the tumor microenvironment and induction of specific immune responses. Preliminary and final data were presented by Prof. ...